P=N/A, N=94, Not yet recruiting, Eskisehir Osmangazi University

P4, N=45, Completed, China Medical University Hospital | Recruiting --> Completed | N=132 --> 45

Rats were randomly assigned to control, model, SSa treatment, and fluoxetine-positive control groups...Mechanistically, SSa restored depleted hippocampal 5-HT levels, reduced pro-inflammatory cytokines expression (TNF-α, IL-6, IL-1β), and suppressed NF-κB p65 activation. These findings demonstrate that SSa exerts therapeutic effect against PTSD-like behavior through dual mechanisms: restoration of hippocampal serotonergic neurotransmission and suppression of NF- κB- mediated neuroinflammation, positioning SSa as a promising candidate for PTSD treatment.

P=N/A, N=296, Recruiting, University of Bern | Active, not recruiting --> Recruiting

Furthermore, reported LDH allosteric inhibitors, including cGmC9 and fluoxetine, preferentially inhibited LDHBtr compared to the native LDHB, by preventing tetramer formation. Overall, this work highlights the central role of tetramerization in regulating LDH activity, and the therapeutic potential of targeting this process. It also establishes LDHBtr as a valuable tool for screening tetramerization disruptors, paving the way for next-generation LDH inhibitors to target cancer metabolism.

Escitalopram and its enantiomer R-citalopram selectively reduced phosphorylation of Akt and its downstream effector FoxO1 while sparing upstream Syk and parallel ERK and PLC-PKC pathways. Similar inhibition under insulin and SDF-1 stimulation indicates a generalized, receptor-independent effect. These findings reveal a noncanonical, SERT-independent mechanism by which escitalopram disrupts PDK1-Akt activation, with potential relevance to the broader intracellular effects of SSRI treatment.

Despite these phenotypic changes, acute 5-HT treatment does not impair the effectiveness of tamoxifen in vitro. In vivo, administration of fluoxetine, a selective serotonin reuptake inhibitor, accelerates tumor growth and increases malignancy in a murine model. These findings underscore the ability of 5-HT to reprogram hormone receptors expression profiles and to promote a more aggressive cancer phenotype.

SeBZF1 (50 mg/kg, intragastrically) or fluoxetine (20 mg/kg, intraperitoneally, i.p, positive control) was administered 30 min before LPS (0.83 mg/kg, i.p.), and behavior assessed 24 h later...SeBZF1 also downregulated cortical IL-4 expression. Overall, SeBZF1 demonstrated antidepressant-like, antioxidant, and anti-inflammatory effects, supporting its potential as a candidate for depression associated with neuroinflammation.

P=N/A, N=160, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital

P4, N=29, Not yet recruiting, The International Peace Maternity and Child Health Hospital; The International Peace Maternity and Child Health Hospital

P=N/A, N=120, Not yet recruiting, Children's Hospital of Soochow University; Children's Hospital of Soochow University

P4, N=200, Not yet recruiting, VA Office of Research and Development | Trial primary completion date: Jun 2026 --> Jun 2030